e-learning
resources
ERJ
2010
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?
Chang K. C, Leung C. C, Yew W. W, Lau T. Y, Leung W. M, Tam C. M, Lam H. C, Tse P. S, Wong M. Y, Lee S. N, Wat K. I, Ma Y. H.
Source:
Eur Respir J 2010; 35: 606-613
Journal Issue:
March
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Chang K. C, Leung C. C, Yew W. W, Lau T. Y, Leung W. M, Tam C. M, Lam H. C, Tse P. S, Wong M. Y, Lee S. N, Wat K. I, Ma Y. H.. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?. Eur Respir J 2010; 35: 606-613
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?
Source: Eur Respir J 2008; 31: 904-905
Year: 2008
Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones},
Source: Eur Respir J 2012; 40: 814-822
Year: 2012
Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction
Source: Eur Respir Rev 2009; 18: 295-299
Year: 2009
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016
Macrolides and lower respiratory tract infections
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=78
Year: 2004
Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?
Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019
Year: 2019
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis
Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020
Year: 2021
Potential antibiotic resistant pathogens in community-acquired pneumonia: playing it safe is anything but
Source: Eur Respir J, 54 (1) 1900870; 10.1183/13993003.00870-2019
Year: 2019
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Are antimicrobials still the future of respiratory infection therapy?
Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections
Year: 2021
Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia?
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections
Source: Eur Respir J 2002; 20: 3S-8S
Year: 2002
Bacterial agents of community-acquired lower respiratory tract infections: observational study on antimicrobial drugs susceptibility
Source: Eur Respir J 2002; 20: Suppl. 38, 421s
Year: 2002
Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2014; 43: 884-897
Year: 2014
Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT)
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis
Source: Eur Respir J 2015; 46: 444-455
Year: 2015
What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?
Source: Eur Respir J 2009; 34: 1492-1494
Year: 2009
Future antibiotics and current practices for treating respiratory tract infections
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=255
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept